NCT04781270View on ClinicalTrials.gov

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

PHASE3RecruitingINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2026

Conditions
Colorectal CarcinomaLiver Metastases
Interventions
DRUG

mFOLFOXIRI regimen

oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1

DRUG

mFOLFOX regimen

oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1

DRUG

Bevacizumab

5 mg/kg on day 1

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04781270 - mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases | Biotech Hunter | Biotech Hunter